(2-氨基-2-甲基丙基)-尿素 | 87484-83-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: (2-氨基-2-甲基丙基)-尿素
• 英文名称: 1,1-dimethyl-2-<(aminocarbonyl)amino>ethylamine
• 英文别名: 1,1-Dimethyl-2-(aminocarbonylamino)ethylamine；(2-Amino-2-methyl-propyl)-urea；(2-amino-2-methylpropyl)urea
• CAS: 87484-83-1
• 化学式: C₅H₁₃N₃O
• 分子量: 131.178
• InChiKey: IJPSRXDFSSPKQT-UHFFFAOYSA-N

物化性质

• 熔点：
  87-90 °C
• 沸点：
  224.7±32.0 °C(Predicted)
• 密度：
  1.054±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  81.1
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  (2-氨基-2-甲基丙基)-尿素 生成 methyl 2-[2-Hydroxy-3-[N-[1,1-dimethyl-2-(aminocarbonylamino)ethyl]amino]propoxy]benzoate
  参考文献：
  名称：

  ERHARDT, PAUL W.;MATIER, WILILAM L.

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2-二氨基-2-甲基丙烷 在 尿素 作用下， 以 氯仿 、 水 为溶剂， 以38%的产率得到(2-氨基-2-甲基丙基)-尿素
  参考文献：
  名称：

  Esters of thiadiazole oxypropanolaine derivatives and pharmaceutical uses

  摘要：

  通用公式为##STR1##的新型化合物，其中R.sub.1是较低的烷基、较低的环烷基、较低的烯基、较低的炔基、较低的烷基羧甲基、芳基羧甲基、芳基或芳基烷基；A是直链键、较低的烷基烯烃或较低的烯烃基；x为1或2，但当x大于1时，##STR2##基的不同发生位置可能相同或不同；Ar为杂环、未取代的芳香族或芳香族取代的较低烷基、较低烯基、较低炔基、较低烷氧基、卤素、乙酰胺基、氨基、硝基、较低烷基氨基、羟基、较低羟基烷基或氰基；W为含有1至约10个碳原子的烷基；B为--NR.sub.2 COR.sub.3、--NR.sub.2 CONR.sub.3 R.sub.4、--NR.sub.2 SO.sub.2 R.sub.3、--NR.sub.2 SO.sub.2 NR.sub.3 R.sub.4或--NR.sub.2 COOR.sub.5，其中R.sub.2、R.sub.3、R.sub.4和R.sub.5可能相同也可能不同，可以是氢、烷基、烷氧基烷基、烷氧基芳基、环烷基、烯基、炔基、芳基、杂环芳基或芳基烷基，但当B为--NR.sub.2 SO.sub.2 R.sub.3或--NR.sub.2 COOR.sub.5时，R.sub.3和R.sub.5不是氢，或者R.sub.3和R.sub.4可以与N一起形成5到7个成员的杂环基团；及其药用盐。

  公开号：

  US04623652A1

文献信息

• Esters of thiadiazole oxypropanolaine derivatives and pharmaceutical uses
  申请人：American Hospital Supply Corporation

  公开号：US04623652A1

  公开（公告）日：1986-11-18

  Novel compounds of the general formula ##STR1## wherein R.sub.1 is lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower alkyl carboxymethyl, aryl carboxymethyl, aryl, or aralkyl; A is a direct bond, lower alkylene, or lower alkenylene; x is 1 or 2, provided that when x is greater than 1, different occurrences of the ##STR2## group may be the same or different; Ar is heterocyclic, unsubstituted aromatic or aromatic substituted with lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halogen, acetamido, amino, nitro, lower alkylamino, hydroxy, lower hydroxyalkyl or cyano; W is alkylene containing from 1 to about 10 carbon atoms; and B is --NR.sub.2 COR.sub.3, --NR.sub.2 CONR.sub.3 R.sub.4, --NR.sub.2 SO.sub.2 R.sub.3, --NR.sub.2 SO.sub.2 NR.sub.3 R.sub.4, or --NR.sub.2 COOR.sub.5, wherein R.sub.2, R.sub.3, R.sub.4 and R.sub.5 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, alkoxyaryl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.3 and R.sub.5 are not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.3 or --NR.sub.2 COOR.sub.5, or R.sub.3 and R.sub.4 may together with N form a 5 to 7 membered heterocyclic group; and the pharmaceutically acceptable salts thereof.

  通用公式为##STR1##的新型化合物，其中R.sub.1是较低的烷基、较低的环烷基、较低的烯基、较低的炔基、较低的烷基羧甲基、芳基羧甲基、芳基或芳基烷基；A是直链键、较低的烷基烯烃或较低的烯烃基；x为1或2，但当x大于1时，##STR2##基的不同发生位置可能相同或不同；Ar为杂环、未取代的芳香族或芳香族取代的较低烷基、较低烯基、较低炔基、较低烷氧基、卤素、乙酰胺基、氨基、硝基、较低烷基氨基、羟基、较低羟基烷基或氰基；W为含有1至约10个碳原子的烷基；B为--NR.sub.2 COR.sub.3、--NR.sub.2 CONR.sub.3 R.sub.4、--NR.sub.2 SO.sub.2 R.sub.3、--NR.sub.2 SO.sub.2 NR.sub.3 R.sub.4或--NR.sub.2 COOR.sub.5，其中R.sub.2、R.sub.3、R.sub.4和R.sub.5可能相同也可能不同，可以是氢、烷基、烷氧基烷基、烷氧基芳基、环烷基、烯基、炔基、芳基、杂环芳基或芳基烷基，但当B为--NR.sub.2 SO.sub.2 R.sub.3或--NR.sub.2 COOR.sub.5时，R.sub.3和R.sub.5不是氢，或者R.sub.3和R.sub.4可以与N一起形成5到7个成员的杂环基团；及其药用盐。
• Development of a Highly Cardioselective Ultra Short-Acting .BETA.-Blocker, ONO-1101.
  作者：Sadahiko IGUCHI、Hiroyuki IWAMURA、Minoru NISHIZAKI、Akio HAYASHI、Kazuhiko SENOKUCHI、Kaoru KOBAYASHI、Katsuhito SAKAKI、Katsutoshi HACHIYA、Yumiko ICHIOKA、Masanori KAWAMURA

  DOI：10.1248/cpb.40.1462

  日期：——

  A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.

  一种新型、高度心脏选择性超短效β受体阻滞剂ONO-1101已研发成功，可用于心动过速的紧急治疗和手术中更好地控制心率。该药物在体内的β受体阻断活性比艾司洛尔强约9倍，在体外的心脏选择性比艾司洛尔强8倍。这种β受体阻断药物的作用时间短，如果出现副作用，停药后即可迅速恢复。它可安全用于急性心脏病患者，是心脏病治疗领域的一大进步。
• Aromatic and esters of hydroxypropylamines
  申请人：American Hospital Supply Corporation

  公开号：US04582855A1

  公开（公告）日：1986-04-15

  Novel compounds of the general formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, --NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3, or --NR.sub.2 COOR.sub.1 wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.3 may together with N form a 5 to 7 momoered heterocyclic group; and the pharmaceutically acceptable salts thereof. These compounds exhibit .beta.-adrenergic blocking activity and are also useful in the treatment of glaucoma.

  通式为##STR1##的新化合物，其中Ar代表取代或未取代的芳香族或杂环基团；W代表1至约10个碳原子的烷基；B代表--NR.sub.2 COR.sub.1、--NR.sub.2 CONR.sub.1 R.sub.3、--NR.sub.2 SO.sub.2 R.sub.1、--NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3或--NR.sub.2 COOR.sub.1，其中R.sub.1、R.sub.2和R.sub.3可以相同也可以不同，可以是氢、烷基、烷氧基烷基、环烷基、烯基、炔基、芳基、杂芳基或芳基烷基，但当B为--NR.sub.2 SO.sub.2 R.sub.1或--NR.sub.2 COOR.sub.1时，R.sub.1不是氢，或者R.sub.1和R.sub.3可以与N一起形成5到7元杂环基团；以及其药学上可接受的盐。这些化合物具有β-肾上腺素受体阻滞活性，并且在青光眼的治疗中也很有用。
• 2-hydroxypropylamine aryl ester derivatives and pharmaceutical use
  申请人：E. I. Du Pont de Nemours and Company

  公开号：US04935421A1

  公开（公告）日：1990-06-19

  Novel compounds of the general formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, --NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3, or --NR.sub.2 COOR.sub.1 wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.3 may together with N form a 5 to 7 membered heterocyclic group; and the pharmaceutically acceptable salts thereof. These compounds exhibit .beta.-adrenergic blocking activity and are also useful in the treatment of glaucoma.

  一般式为##STR1##的新化合物，其中Ar代表取代或未取代的芳香或杂环基；W代表1至约10个碳原子的烷基；B代表--NR.sub.2 COR.sub.1、--NR.sub.2 CONR.sub.1 R.sub.3、--NR.sub.2 SO.sub.2 R.sub.1、--NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3或--NR.sub.2 COOR.sub.1，其中R.sub.1、R.sub.2和R.sub.3可以相同或不同，可以是氢、烷基、烷氧基烷基、环烷基、烯基、炔基、芳基、杂芳基或芳基烷基，但当B为--NR.sub.2 SO.sub.2 R.sub.1或--NR.sub.2 COOR.sub.1时，R.sub.1不是氢，或者R.sub.1和R.sub.3可以与N一起形成5到7个成员的杂环基；以及其药学上可接受的盐。这些化合物表现出β-肾上腺素能阻断活性，并且在青光眼的治疗中也有用。
• 2-hydroxypropylamine aryl ester derivatives
  申请人：E. I. du Pont de Nemours and Company

  公开号：US04810717A1

  公开（公告）日：1989-03-07

  Novel compounds of the general formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, --NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3, or --NR.sub.2 COOR.sub.1 wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.3 may together with N form a 5 to 7 membered heterocyclic group; and the pharmaceutically acceptable salts thereof. These compounds exhibit .beta.-adrenergic blocking activity and are also useful in the treatment of glaucoma.

  通式为##STR1##的新化合物，其中Ar代表取代或未取代的芳香或杂环基团；W代表1至约10个碳原子的烷基；B代表--NR.sub.2 COR.sub.1，--NR.sub.2 CONR.sub.1 R.sub.3，--NR.sub.2 SO.sub.2 R.sub.1，--NR.sub.2 SO.sub.2 NR.sub.1 R.sub.3或--NR.sub.2 COOR.sub.1，其中R.sub.1，R.sub.2和R.sub.3可以相同或不同，可以是氢，烷基，烷氧基烷基，环烷基，烯基，炔基，芳基，杂芳基或芳基烷基，但当B为--NR.sub.2 SO.sub.2 R.sub.1或--NR.sub.2 COOR.sub.1时，R.sub.1不是氢，或R.sub.1和R.sub.3可以与N一起形成5到7个成员的杂环基团；以及其药学上可接受的盐。这些化合物表现出β-肾上腺素能阻滞活性，并且在青光眼的治疗中也有用。